Reza Heidari

Dr. Reza Heidari

Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shīrāz, Fārs, Iran
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
RHReza Heidari
Reza Heidari
AAAsrin Ahmadi
Asrin Ahmadi
HMHamidreza Mohammadi
Hamidreza Mohammadi
Mohammad Mehdi OmmatiMohammad Mehdi Ommati
Mohammad Mehdi Ommati
NANegar Azarpira
Negar Azarpira
HNHossein Niknahad
Hossein Niknahad

11 January 2019 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
HDHesam Dorosti
Hesam Dorosti
MEMahboobeh Eslami
Mahboobeh Eslami
MNManica Negahdaripour
Manica Negahdaripour
MGMohammad Bagher Ghoshoon
Mohammad Bagher Ghoshoon
Ahmad GholamiAhmad Gholami
Ahmad Gholami
YGYounes Ghasemi
Younes Ghasemi
Streptococcus pneumoniae is a leading cause of some diseases such as pneumonia, sepsis, and meningitis mostly in children less than 5 years of age. Presently, two types of pneumococcal vaccine are available on the market: polysaccharide vaccines (PPV) that are based on capsular polysaccharides of at least 92 different serotypes, and protein-conjugated polysaccharide vaccine (PCV). The PPVs such as PPV23 do not stimulate efficient protective immunity in children under 2 years old, while the PCVs such as PCV7, PCV10, and PCV13 that cover 7, 10, and 13 serotypes, respectively, highly protect newborns, but have some disadvantages such as complications in manufacturing, costly production, and also requires refrigeration and multiple injections. Epitope-based vaccines, including varied mixtures of conserved virulence proteins, are a promising alternative to the existing capsular antigen vaccines. In this study, it has been tried to design an efficient subunit vaccine in order to elicit both CTL and HTL responses. The immunodominant epitopes from highly protective antigens of S. pneumoniae (PspA, CbpA, PiuA, and PhtD) were selected from different databanks, such as IEDB, PROPRED, RANKPEP, and MHCPRED. The PspA and CbpA were chosen as CTL epitope stimulants, and PhtD and PiuA were defined as helper epitopes. Because of low immunogenicity of epitope vaccines, PorB protein as a TLR2 agonist was employed to increase the immunogenicity of the vaccine. All the peptide segments were fused to each other by proper linkers, and the physicochemical, structural, and immunological characteristics of the construct were also evaluated. To achieve a high-quality 3 D structure of the protein, modeling, refinement, and validation of the final construct were done. Docking and molecular dynamics analyses demonstrated an appropriate and stable interaction between the vaccine and TLR2 during the simulation period. The computational studies suggested the designed vaccine as a novel construct, capable to elicit efficient humoral and cellular immunities, which are crucial for protection against S. pneumoniae. Communicated by Ramaswamy H. Sarma

1 July 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
RHReza Heidari
Reza Heidari
HNHossein Niknahad
Hossein Niknahad
ASAla Sadeghi
Ala Sadeghi
HMHamidreza Mohammadi
Hamidreza Mohammadi
VGVahid Ghanbarinejad
Vahid Ghanbarinejad
AJAkram Jamshidzadeh
Akram Jamshidzadeh

1 February 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
AJAkram Jamshidzadeh
Akram Jamshidzadeh
RHReza Heidari
Reza Heidari
MAMozhgan Abasvali
Mozhgan Abasvali
MZMehdi Zarei
Mehdi Zarei
Mohammad Mehdi OmmatiMohammad Mehdi Ommati
Mohammad Mehdi Ommati
ANAsma Najibi
Asma Najibi

1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RHReza Heidari
Reza Heidari
SBShima Behnamrad
Shima Behnamrad
ZKZahra Khodami
Zahra Khodami
Mohammad Mehdi OmmatiMohammad Mehdi Ommati
Mohammad Mehdi Ommati
NANegar Azarpira
Negar Azarpira
AVAfsaneh Vazin
Afsaneh Vazin
Colistin (COL) belongs to the polymixin class of antibiotics used as the last line antibiotic against drug-resistant infections. However, nephrotoxicity is the major deleterious and dose-limiting side effect associated with COL therapy. Oxidative stress and mitochondrial impairment are suspected mechanisms involved in COL-induced nephrotoxicity. Taurine is one of the most abundant amino acids in the human body with antioxidant and mitochondria protecting properties. The current study was designed to evaluate the potential nephroprotective properties of taurine against COL-associated nephrotoxicity. Mice were treated with COL (15 mg/kg/day, i.v, for 7 consecutive days) alone or in combination with taurine (500 and 1000 mg/kg, i.p). Plasma biomarkers of nephrotoxicity in addition of kidney tissue markers of oxidative stress were evaluated. Additionally, kidney mitochondria were isolated, and several mitochondrial indices were assessed. The COL-associated renal injury was evident by a significant increase in plasma markers of renal injury including creatinine (Cr), and blood urine nitrogen (BUN). COL treatment also caused a significant increase in kidney reactive oxygen species (ROS) and lipid peroxidation (LPO). Renal GSH reservoirs and antioxidant capacity were also decreased in COL-treated animals. Mitochondrial parameters including mitochondrial dehydrogenase activity, membrane potential, GSH, and ATP were significantly decreased while mitochondrial LPO, permeabilization, and GSSG content were increased in the kidney of COL-treated mice. It was found that taurine (500 and 1000 mg/kg, i.p) treatment alleviated COL-induced oxidative stress and mitochondrial dysfunction in the kidney tissue. The data obtained from the current study suggest mitochondrial dysfunction and oxidative stress as fundamental mechanisms of renal injury induced by COL. On the other hand, taurine supplementation protected kidney through decreasing oxidative stress and regulating mitochondrial function.

1 January 2016 in Toxicology Reports
Verified
Journal Article
Open access
RHReza Heidari
Reza Heidari
AJAkram Jamshidzadeh
Akram Jamshidzadeh
HNHossein Niknahad
Hossein Niknahad
EMElnaz Mardani
Elnaz Mardani
Mohammad Mehdi OmmatiMohammad Mehdi Ommati
Mohammad Mehdi Ommati
ANAsma Najibi
Asma Najibi
Hyperammonemia is associated with chronic and acute liver injury. There is no promising therapeutic agent against ammonia-induced complications. Hence, finding therapeutic molecules with safe profile of administration has clinical value. The present study was conducted to evaluate the role of taurine (TA) administration on plasma and brain ammonia and its consequent events in different models of chronic and acute liver injury and hyperammonemia. Bile duct ligated (BDL) rats were used as a model of chronic liver injury. Thioacetamide and acetaminophen-induced acute liver failure were used as acute liver injury models. A high level of ammonia was detected in blood and brain of experimental groups. An increase in brain ammonia level coincided with a decreased total locomotor activity of animals and significant changes in the biochemistry of blood and also liver tissue. TA administration (500 and 1000 mg/kg, i.p), effectively alleviated liver injury and its consequent events including rise in plasma and brain ammonia and brain edema. The data suggested that TA is not only a useful and safe agent to preserve liver function, but also prevented hyperammonemia as a deleterious consequence of acute and chronic liver injury.